Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis
Objective Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a ≥50% reduction in the development of new erosions...
Gespeichert in:
| Veröffentlicht in: | Arthritis and rheumatism 2006-05, Vol.54 (5), p.1410-1414 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1414 |
|---|---|
| container_issue | 5 |
| container_start_page | 1410 |
| container_title | Arthritis and rheumatism |
| container_volume | 54 |
| creator | Jarrett, Stephen J. Conaghan, Philip G. Sloan, Victor S. Papanastasiou, Philemon Ortmann, Christine‐Elke O'Connor, Philip J. Grainger, Andrew J. Emery, Paul |
| description | Objective
Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a ≥50% reduction in the development of new erosions on magnetic resonance imaging (MRI) in patients with early RA.
Methods
In this proof‐of‐concept study, 39 patients with early RA and clinical synovitis of the hand/wrist were randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at baseline and week 13. Patients in both groups received methotrexate (MTX) at a dosage of 7.5–20 mg/week. MRI and plain radiography were performed at baseline and week 26.
Results
At week 26, the mean ± SD change in MRI hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0.9 ± 1.63 versus 2.3 ± 3.09; P = 0.176). The mean ± SD increase in the number of hand and wrist bones with erosions was 0.3 ± 0.75 for zoledronic acid compared with 1.4 ± 1.77 for placebo (P = 0.029). The proportion of patients in whom new MRI‐visualized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (33% versus 58%; P = 0.121). The zoledronic acid group had a mean change in the number of radiographic erosions of 0.1 compared with 0.5 for the placebo group (P = 0.677). The safety profile of zoledronic acid was similar to that of placebo.
Conclusion
The results of this study suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstrated by consistent results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone. |
| doi_str_mv | 10.1002/art.21824 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67946557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67946557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4504-1ce58caec18ab9048eda998744a4eb03c54756ffcf964bd7175de9e9172f6f713</originalsourceid><addsrcrecordid>eNqF0d1rFDEQAPAgij2rD_4DkhcFH65NdvOxeSzFLygoUp-X2eyEi2STM8m2nH-9qXfQJzEQQsKPmckMIa85u-CMdZeQ60XHh048IRsuO7NlvOdPyYYxJra9NPyMvCjlZ7t2veyfkzOulJBGDRuyfssY_OIj5APFOz9jtEhdyhRoqXm1dc0Q6IQRna80OVp3SCPe08mX_S497AgV6e8UcM4pekvB-pn6SBFyONC8w3WBmtpbq3OXffXlJXnmIBR8dTrPyY-PH26vP29vvn76cn11s7VCttK5RTlYQMsHmAwTA85gzKCFAIET660UWirnrDNKTLPmWs5o0HDdOeU078_Ju2PcfU6_Vix1XHyxGAJETGsZlTZCSan_C3mLzdtq8P0R2pxKyejGffZLa97I2fgwjLF9cvw7jGbfnIKu04Lzozx1v4G3JwDFQnAZovXl0WmttORdc5dHd-8DHv6dcbz6fntM_QcgAqLd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17171111</pqid></control><display><type>article</type><title>Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Jarrett, Stephen J. ; Conaghan, Philip G. ; Sloan, Victor S. ; Papanastasiou, Philemon ; Ortmann, Christine‐Elke ; O'Connor, Philip J. ; Grainger, Andrew J. ; Emery, Paul</creator><creatorcontrib>Jarrett, Stephen J. ; Conaghan, Philip G. ; Sloan, Victor S. ; Papanastasiou, Philemon ; Ortmann, Christine‐Elke ; O'Connor, Philip J. ; Grainger, Andrew J. ; Emery, Paul</creatorcontrib><description>Objective
Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a ≥50% reduction in the development of new erosions on magnetic resonance imaging (MRI) in patients with early RA.
Methods
In this proof‐of‐concept study, 39 patients with early RA and clinical synovitis of the hand/wrist were randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at baseline and week 13. Patients in both groups received methotrexate (MTX) at a dosage of 7.5–20 mg/week. MRI and plain radiography were performed at baseline and week 26.
Results
At week 26, the mean ± SD change in MRI hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0.9 ± 1.63 versus 2.3 ± 3.09; P = 0.176). The mean ± SD increase in the number of hand and wrist bones with erosions was 0.3 ± 0.75 for zoledronic acid compared with 1.4 ± 1.77 for placebo (P = 0.029). The proportion of patients in whom new MRI‐visualized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (33% versus 58%; P = 0.121). The zoledronic acid group had a mean change in the number of radiographic erosions of 0.1 compared with 0.5 for the placebo group (P = 0.677). The safety profile of zoledronic acid was similar to that of placebo.
Conclusion
The results of this study suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstrated by consistent results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.</description><identifier>ISSN: 0004-3591</identifier><identifier>EISSN: 1529-0131</identifier><identifier>DOI: 10.1002/art.21824</identifier><identifier>PMID: 16645968</identifier><identifier>CODEN: ARHEAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; Bone Density Conservation Agents - therapeutic use ; Bones, joints and connective tissue. Antiinflammatory agents ; Diphosphonates - therapeutic use ; Diseases of the osteoarticular system ; Double-Blind Method ; Female ; Humans ; Imidazoles - therapeutic use ; Inflammatory joint diseases ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Arthritis and rheumatism, 2006-05, Vol.54 (5), p.1410-1414</ispartof><rights>Copyright © 2006 by the American College of Rheumatology</rights><rights>2006 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4504-1ce58caec18ab9048eda998744a4eb03c54756ffcf964bd7175de9e9172f6f713</citedby><cites>FETCH-LOGICAL-c4504-1ce58caec18ab9048eda998744a4eb03c54756ffcf964bd7175de9e9172f6f713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.21824$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.21824$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27928,27929,45578,45579</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17767512$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16645968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jarrett, Stephen J.</creatorcontrib><creatorcontrib>Conaghan, Philip G.</creatorcontrib><creatorcontrib>Sloan, Victor S.</creatorcontrib><creatorcontrib>Papanastasiou, Philemon</creatorcontrib><creatorcontrib>Ortmann, Christine‐Elke</creatorcontrib><creatorcontrib>O'Connor, Philip J.</creatorcontrib><creatorcontrib>Grainger, Andrew J.</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><title>Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis</title><title>Arthritis and rheumatism</title><addtitle>Arthritis Rheum</addtitle><description>Objective
Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a ≥50% reduction in the development of new erosions on magnetic resonance imaging (MRI) in patients with early RA.
Methods
In this proof‐of‐concept study, 39 patients with early RA and clinical synovitis of the hand/wrist were randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at baseline and week 13. Patients in both groups received methotrexate (MTX) at a dosage of 7.5–20 mg/week. MRI and plain radiography were performed at baseline and week 26.
Results
At week 26, the mean ± SD change in MRI hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0.9 ± 1.63 versus 2.3 ± 3.09; P = 0.176). The mean ± SD increase in the number of hand and wrist bones with erosions was 0.3 ± 0.75 for zoledronic acid compared with 1.4 ± 1.77 for placebo (P = 0.029). The proportion of patients in whom new MRI‐visualized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (33% versus 58%; P = 0.121). The zoledronic acid group had a mean change in the number of radiographic erosions of 0.1 compared with 0.5 for the placebo group (P = 0.677). The safety profile of zoledronic acid was similar to that of placebo.
Conclusion
The results of this study suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstrated by consistent results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.</description><subject>Adult</subject><subject>Aged</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Diphosphonates - therapeutic use</subject><subject>Diseases of the osteoarticular system</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Inflammatory joint diseases</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0004-3591</issn><issn>1529-0131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0d1rFDEQAPAgij2rD_4DkhcFH65NdvOxeSzFLygoUp-X2eyEi2STM8m2nH-9qXfQJzEQQsKPmckMIa85u-CMdZeQ60XHh048IRsuO7NlvOdPyYYxJra9NPyMvCjlZ7t2veyfkzOulJBGDRuyfssY_OIj5APFOz9jtEhdyhRoqXm1dc0Q6IQRna80OVp3SCPe08mX_S497AgV6e8UcM4pekvB-pn6SBFyONC8w3WBmtpbq3OXffXlJXnmIBR8dTrPyY-PH26vP29vvn76cn11s7VCttK5RTlYQMsHmAwTA85gzKCFAIET660UWirnrDNKTLPmWs5o0HDdOeU078_Ju2PcfU6_Vix1XHyxGAJETGsZlTZCSan_C3mLzdtq8P0R2pxKyejGffZLa97I2fgwjLF9cvw7jGbfnIKu04Lzozx1v4G3JwDFQnAZovXl0WmttORdc5dHd-8DHv6dcbz6fntM_QcgAqLd</recordid><startdate>200605</startdate><enddate>200605</enddate><creator>Jarrett, Stephen J.</creator><creator>Conaghan, Philip G.</creator><creator>Sloan, Victor S.</creator><creator>Papanastasiou, Philemon</creator><creator>Ortmann, Christine‐Elke</creator><creator>O'Connor, Philip J.</creator><creator>Grainger, Andrew J.</creator><creator>Emery, Paul</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>200605</creationdate><title>Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis</title><author>Jarrett, Stephen J. ; Conaghan, Philip G. ; Sloan, Victor S. ; Papanastasiou, Philemon ; Ortmann, Christine‐Elke ; O'Connor, Philip J. ; Grainger, Andrew J. ; Emery, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4504-1ce58caec18ab9048eda998744a4eb03c54756ffcf964bd7175de9e9172f6f713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Diphosphonates - therapeutic use</topic><topic>Diseases of the osteoarticular system</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Inflammatory joint diseases</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>online_resources</toplevel><creatorcontrib>Jarrett, Stephen J.</creatorcontrib><creatorcontrib>Conaghan, Philip G.</creatorcontrib><creatorcontrib>Sloan, Victor S.</creatorcontrib><creatorcontrib>Papanastasiou, Philemon</creatorcontrib><creatorcontrib>Ortmann, Christine‐Elke</creatorcontrib><creatorcontrib>O'Connor, Philip J.</creatorcontrib><creatorcontrib>Grainger, Andrew J.</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jarrett, Stephen J.</au><au>Conaghan, Philip G.</au><au>Sloan, Victor S.</au><au>Papanastasiou, Philemon</au><au>Ortmann, Christine‐Elke</au><au>O'Connor, Philip J.</au><au>Grainger, Andrew J.</au><au>Emery, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis</atitle><jtitle>Arthritis and rheumatism</jtitle><addtitle>Arthritis Rheum</addtitle><date>2006-05</date><risdate>2006</risdate><volume>54</volume><issue>5</issue><spage>1410</spage><epage>1414</epage><pages>1410-1414</pages><issn>0004-3591</issn><eissn>1529-0131</eissn><coden>ARHEAW</coden><abstract>Objective
Bisphosphonates inhibit osteoclast activity, which is central to the development of bone damage in rheumatoid arthritis (RA). The aim of this study was to assess whether treatment with zoledronic acid, compared with placebo, could achieve a ≥50% reduction in the development of new erosions on magnetic resonance imaging (MRI) in patients with early RA.
Methods
In this proof‐of‐concept study, 39 patients with early RA and clinical synovitis of the hand/wrist were randomized to receive infusions with either zoledronic acid (5 mg) or placebo, administered at baseline and week 13. Patients in both groups received methotrexate (MTX) at a dosage of 7.5–20 mg/week. MRI and plain radiography were performed at baseline and week 26.
Results
At week 26, the mean ± SD change in MRI hand and wrist erosions was 61% lower in the zoledronic acid group compared with the placebo group (0.9 ± 1.63 versus 2.3 ± 3.09; P = 0.176). The mean ± SD increase in the number of hand and wrist bones with erosions was 0.3 ± 0.75 for zoledronic acid compared with 1.4 ± 1.77 for placebo (P = 0.029). The proportion of patients in whom new MRI‐visualized bone edema developed was smaller in the zoledronic acid group compared with the placebo group (33% versus 58%; P = 0.121). The zoledronic acid group had a mean change in the number of radiographic erosions of 0.1 compared with 0.5 for the placebo group (P = 0.677). The safety profile of zoledronic acid was similar to that of placebo.
Conclusion
The results of this study suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstrated by consistent results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16645968</pmid><doi>10.1002/art.21824</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-3591 |
| ispartof | Arthritis and rheumatism, 2006-05, Vol.54 (5), p.1410-1414 |
| issn | 0004-3591 1529-0131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67946557 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Biological and medical sciences Bone Density Conservation Agents - therapeutic use Bones, joints and connective tissue. Antiinflammatory agents Diphosphonates - therapeutic use Diseases of the osteoarticular system Double-Blind Method Female Humans Imidazoles - therapeutic use Inflammatory joint diseases Magnetic Resonance Imaging Male Medical sciences Middle Aged Pharmacology. Drug treatments |
| title | Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T02%3A49%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20evidence%20for%20a%20structural%20benefit%20of%20the%20new%20bisphosphonate%20zoledronic%20acid%20in%20early%20rheumatoid%20arthritis&rft.jtitle=Arthritis%20and%20rheumatism&rft.au=Jarrett,%20Stephen%20J.&rft.date=2006-05&rft.volume=54&rft.issue=5&rft.spage=1410&rft.epage=1414&rft.pages=1410-1414&rft.issn=0004-3591&rft.eissn=1529-0131&rft.coden=ARHEAW&rft_id=info:doi/10.1002/art.21824&rft_dat=%3Cproquest_cross%3E67946557%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17171111&rft_id=info:pmid/16645968&rfr_iscdi=true |